Table 2.
Clinical Characteristics of Patients in the Training and Validation Datasets with Cervical Cancer
| Variable | Training Set |
Validation Set |
||
|---|---|---|---|---|
| GEO: GSE44001 | TCGA | GEO: GSE39001 | GEO: GSE52094 | |
| Patients used, n | 300 | 290 | 21 | 55 |
| Median age (range), years | 46 (20–88) | 43 (32–67) | 50 (24–74) | |
| Tumor size | ||||
| <4 cm | 218 | |||
| ≥4 cm | 82 | |||
| FIGO stage (n) | ||||
| I | 258 | 155 | 14 | 27 |
| II | 42 | 66 | 7 | 8 |
| III | 0 | 42 | 0 | 16 |
| IV | 0 | 21 | 0 | 4 |
| DFS (range), months | 47.5 (0.43–104.13) | |||
| Follow-up (range), months | 61 (17–93) | 58 (1–86) | ||
| OS (range), months | 18.4 (0.03–214) | |||
| Hysterectomy | ||||
| Yes | 155 | 11 | 15 | |
| No | 9 | 10 | 40 | |
| Radiotherapy | ||||
| Yes | 175 | 17 | 41 | |
| No | 63 | 4 | 14 | |
| Chemotherapy | ||||
| Yes | 145 | 11 | 23 | |
| No | 144 | 10 | 32 | |
| Molecular-targeted therapy | ||||
| Yes | 84 | |||
| No | 44 | |||
DFS, disease-free survival; FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; TCGA, The Cancer Genome Atlas.